Acta Scientific Clinical Case Reports

EditorialVolume 4 Issue 4

The Trajectory of Recent Developments in Atherosclerosis

Leyla Bahar*

Department of Stem Cell and Regenerative Medicine, Institute of Health Sciences, Mersin University, Mersin, Turkey

*Corresponding Author: Leyla Bahar, Department of Stem Cell and Regenerative Medicine, Institute of Health Sciences, Mersin University, Mersin, Turkey.

Received: January 27, 2023; Published: March 01, 2023


Atherosclerosis is one of the most common causes of cardiovascular disease (CVD), accounting for approximately 7.2 million deaths each year. The American Heart Association stated that the prevalence of atherosclerosis will increase by 18% by 2030 [1]. Atherosclerosis is a chronic inflammatory disease of the great arteries that is the main cause of cardiovascular disease and stroke [2]. Atherosclerosis is an inflammatory disease of the great and important arteries that is the main source of stroke and CVD. It is assumed that atherosclerosis is caused by many factors including environmental and genetic.


  1. Benjamin EJ., et al. “Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association”. Circulation 137 (2018): e67-e492.
  2. Kong P., et al. “Inflammation and atherosclerosis: signaling pathways and therapeutic intervention”. Signal Transduction and Targeted Therapy 1 (2022): 131.
  3. Fan J and Watanabe T. “Atherosclerosis: Known and unknown”. Pathology International3 (2022): 151-160.
  4. Shao C., et al. “Coronary artery disease: from mechanism to clinical practice”. Advances in Experimental Medicine and Biology 1177 (2020): 1-36.
  5. Jebari-Benslaiman S., et al. “Pathophysiology of Atherosclerosis”. International Journal of Molecular Sciences 6 (2022): 3346.
  6. Takahashi K., et al. “Multifunctional roles of macrophages in the development and progression of atherosclerosis in humans and experimental animals”. Medical Electron Microscopy 4 (2002): 179-203.
  7. Björkegren JL M and Lusis AJ. “Atherosclerosis: Recent developments”. Cell10 (2022): 1630-1645.
  8. Luo Y., et al. “Macrophagic CD146 promotes foam cell formation and retention during atherosclerosis”. Cell Research3 (2017): 352-372.
  9. Farahi L., et al. “Roles of Macrophages in Atherogenesis”. Frontiers in Pharmacology 12 (2021): 785220.
  10. Wang L., et al. “Potential Mechanisms and Effects of Efferocytosis in Atherosclerosis”. Frontiers in Endocrinology (Lausanne) 11 (2020): 585285.
  11. Carlström M. “Nitric oxide signalling in kidney regulation and cardiometabolic health”. Nature Reviews Nephrology9 (2021): 575-590.
  12. Loirand G., et al. “Urotensin II and atherosclerosis”. Peptides5 (2008): 778-782.
  13. Rex DAB., et al. “The network map of urotensin-II mediated signaling pathway in physiological and pathological conditions”. Cell Communication and Signaling 16 (2022).
  14. Shiraishi Y., et al. “Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice”. Journal of Hypertension10 (2008): 1955-1965.
  15. Poznyak A V., et al. “Vaccination against Atherosclerosis: Is It Real?”. International Journal of Molecular Sciences5 (2022): 2417.
  16. Bahar L and Tuysuz ME. “The relation of left internal mammary artery atherosclerosis with urotensin-II”. Bratislavske Lekarske Listy7 (2020): 516-521.

Citation: Leyla Bahar. “The Trajectory of Recent Developments in Atherosclerosis". Acta Scientific Clinical Case Reports 4.4 (2023): 01-03.

Copyright: © 2022 Leyla Bahar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

News and Events

Contact US